be 4-4-4-4 profile

BE 4-4-4-4: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

ID Source	ID
PubMed CID	368998
CHEMBL ID	551489
SCHEMBL ID	429223
MeSH ID	M0220441

Synonym
NCI60_013495
NCIMECH_000262
NSC640506 ,
PDSP2_000331
PDSP1_000333
3,8,13,18-pentaazapentacosane pentahydrochloride
1, 4-butanediamine, {n-[4-(ethylamino)butyl]-n'-[4-[[4-(ethylamino)butyl]amino]butyl]-,} pentahydrochloride
sl-11061
n-ethyl-n'-[4-[4-[4-(ethylamino)butylamino]butylamino]butyl]butane-1,4-diamine
ethyl[4-({4-[(4-{[4-(ethylamino)butyl]amino}butyl)amino]butyl}amino)butyl]amine
n~1~-ethyl-n~4~-(4-((4-((4-(ethylamino)butyl)amino)butyl)amino)butyl)-1,4-butanediamine hydrochloride
147510-59-6
CHEMBL551489
3,8,13,18,23-pentaazapentacosane
1,19-bis(ethylamino)-5,10,15-triazanonadecane
be4444
cas_147510-59-6
bdbm86161
papc-hcl
be 4-4-4-4
1,4-butanediamine, n-(4-(ethylamino)butyl)-n'-(4-((4-(ethylamino)butyl)amino)butyl)-
SCHEMBL429223
DTXSID50163735

Excerpt	Reference	Relevance
" dose of 20 mg/kg ranged between 30 and 33 microgram/ml, the terminal elimination half-life was 94 min, and the volume of distribution (Vdss) was 850 ml/kg."	( Plasma pharmacokinetics and urinary excretion of the polyamine analogue 1, 19-bis(ethylamino)-5, 10, 15-triazanonadecane in CD2F1 mice. Callery, PS; Eddington, ND; Egorin, MJ; Eiseman, JL; Sentz, DL; Yuan, ZM, 1996)	0.29

Excerpt	Relevance	Reference
" Urinary excretion of parent BE-4-4-4-4 in the first 24 h after dosing accounted for less than 30% of the delivered dose."	( Plasma pharmacokinetics and urinary excretion of the polyamine analogue 1, 19-bis(ethylamino)-5, 10, 15-triazanonadecane in CD2F1 mice. Callery, PS; Eddington, ND; Egorin, MJ; Eiseman, JL; Sentz, DL; Yuan, ZM, 1996)	0.29

Assay ID	Title	Year	Journal	Article
AID421192	Antitumor activity against human LNCAP cells	2009	Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15	Recent advances in the development of polyamine analogues as antitumor agents.
AID421191	Antitumor activity against human DU145 cells	2009	Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15	Recent advances in the development of polyamine analogues as antitumor agents.
AID421193	Antitumor activity against human PC3 cells	2009	Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15	Recent advances in the development of polyamine analogues as antitumor agents.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	15 (83.33)	18.2507
2000's	3 (16.67)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	1 (5.26%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	18 (94.74%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Classes	Roles
putrescine [no description available]	2.68	3	alkane-alpha,omega-diamine	antioxidant; fundamental metabolite
spermidine [no description available]	2.68	3	polyazaalkane; triamine	autophagy inducer; fundamental metabolite; geroprotector
spermine [no description available]	4.19	17	polyazaalkane; tetramine	antioxidant; fundamental metabolite; immunosuppressive agent
carmustine Carmustine: A cell-cycle phase nonspecific alkylating antineoplastic agent. It is used in the treatment of brain tumors and various other malignant neoplasms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p462) This substance may reasonably be anticipated to be a carcinogen according to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (From Merck Index, 11th ed). carmustine : A member of the class of N-nitrosoureas that is 1,3-bis(2-chloroethyl)urea in which one of the nitrogens is substituted by a nitroso group.	1.98	1	N-nitrosoureas; organochlorine compound	alkylating agent; antineoplastic agent
eflornithine Eflornithine: An inhibitor of ORNITHINE DECARBOXYLASE, the rate limiting enzyme of the polyamine biosynthetic pathway.. eflornithine : A fluoroamino acid that is ornithine substituted by a difluoromethyl group at position 2.	1.99	1	alpha-amino acid; fluoroamino acid	trypanocidal drug
entinostat [no description available]	3.14	1	benzamides; carbamate ester; primary amino compound; pyridines; substituted aniline	antineoplastic agent; apoptosis inducer; EC 3.5.1.98 (histone deacetylase) inhibitor
n(1),n(11)-diethylnorspermine N(1),N(11)-diethylnorspermine: structure given in first source	4.35	6
n(1), n(12)-diethylspermine N(1), N(12)-diethylspermine: structure in first source. N(1),N(12)-diethylspermine : A substituted spermine that is spermine in which a hydrogen attached to each of the primary amino groups has been replaced by an ethyl group.	3.52	2	polyazaalkane; secondary amino compound; substituted spermine; tetramine	antineoplastic agent
vorinostat Vorinostat: A hydroxamic acid and anilide derivative that acts as a HISTONE DEACETYLASE inhibitor. It is used in the treatment of CUTANEOUS T-CELL LYMPHOMA and SEZARY SYNDROME.. vorinostat : A dicarboxylic acid diamide comprising suberic (octanedioic) acid coupled to aniline and hydroxylamine. A histone deacetylase inhibitor, it is marketed under the name Zolinza for the treatment of cutaneous T cell lymphoma (CTCL).	3.14	1	dicarboxylic acid diamide; hydroxamic acid	antineoplastic agent; apoptosis inducer; EC 3.5.1.98 (histone deacetylase) inhibitor
etoposide [no description available]	1.98	1	beta-D-glucoside; furonaphthodioxole; organic heterotetracyclic compound	antineoplastic agent; DNA synthesis inhibitor
n(1),n(14)-bis(ethyl)homospermine N(1),N(14)-bis(ethyl)homospermine: structure given in first source; depletes polyamines and inhibits the growth of tumor cells in tissue culture	3.51	2
mdl 27695 MDL 27695: structure given in first source	3.14	1
trichostatin a trichostatin A: chelates zinc ion in the active site of histone deacetylases, resulting in preventing histone unpacking so DNA is less available for transcription; do not confuse with TRICHOSANTHIN which is a protein; found in STREPTOMYCES	3.14	1	antibiotic antifungal agent; hydroxamic acid; trichostatin	bacterial metabolite; EC 3.5.1.98 (histone deacetylase) inhibitor; geroprotector
cgc 11047 CGC 11047: may prove useful in promoting regression of choroidal neovascularization	3.14	1

Condition	Relationship Strength	Studies
Breast Cancer [description not available]	2.96	1
Breast Neoplasms Tumors or cancer of the human BREAST.	2.96	1
Benign Neoplasms, Brain [description not available]	2.9	4
Brain Neoplasms Neoplasms of the intracranial components of the central nervous system, including the cerebral hemispheres, basal ganglia, hypothalamus, thalamus, brain stem, and cerebellum. Brain neoplasms are subdivided into primary (originating from brain tissue) and secondary (i.e., metastatic) forms. Primary neoplasms are subdivided into benign and malignant forms. In general, brain tumors may also be classified by age of onset, histologic type, or presenting location in the brain.	2.9	4
Carcinoma, Epidermoid [description not available]	2.39	2
Cancer of Head [description not available]	1.98	1
Carcinoma, Squamous Cell A carcinoma derived from stratified SQUAMOUS EPITHELIAL CELLS. It may also occur in sites where glandular or columnar epithelium is normally present. (From Stedman, 25th ed)	2.39	2
Head and Neck Neoplasms Soft tissue tumors or cancer arising from the mucosal surfaces of the LIP; oral cavity; PHARYNX; LARYNX; and cervical esophagus. Other sites included are the NOSE and PARANASAL SINUSES; SALIVARY GLANDS; THYROID GLAND and PARATHYROID GLANDS; and MELANOMA and non-melanoma skin cancers of the head and neck. (from Holland et al., Cancer Medicine, 4th ed, p1651)	1.98	1
Body Weight The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms.	1.98	1
Cancer of Colon [description not available]	1.98	1
Astrocytoma, Grade IV [description not available]	1.98	1
Cancer of Lung [description not available]	1.98	1
Colonic Neoplasms Tumors or cancer of the COLON.	1.98	1
Glioblastoma A malignant form of astrocytoma histologically characterized by pleomorphism of cells, nuclear atypia, microhemorrhage, and necrosis. They may arise in any region of the central nervous system, with a predilection for the cerebral hemispheres, basal ganglia, and commissural pathways. Clinical presentation most frequently occurs in the fifth or sixth decade of life with focal neurologic signs or seizures.	1.98	1
Lung Neoplasms Tumors or cancer of the LUNG.	1.98	1
Cancer of Prostate [description not available]	2.69	3
Prostatic Neoplasms Tumors or cancer of the PROSTATE.	2.69	3
Leukemia L 1210 [description not available]	1.99	1
Sensitivity and Specificity Binary classification measures to assess test results. Sensitivity or recall rate is the proportion of true positives. Specificity is the probability of correctly determining the absence of a condition. (From Last, Dictionary of Epidemiology, 2d ed)	1.99	1
Adenocarcinoma, Basal Cell [description not available]	1.99	1
Adenocarcinoma A malignant epithelial tumor with a glandular organization.	1.99	1
Argentaffinoma [description not available]	1.99	1
Carcinoid Tumor A usually small, slow-growing neoplasm composed of islands of rounded, oxyphilic, or spindle-shaped cells of medium size, with moderately small vesicular nuclei, and covered by intact mucosa with a yellow cut surface. The tumor can occur anywhere in the gastrointestinal tract (and in the lungs and other sites); approximately 90% arise in the appendix. It is now established that these tumors are of neuroendocrine origin and derive from a primitive stem cell. (From Stedman, 25th ed & Holland et al., Cancer Medicine, 3d ed, p1182)	1.99	1

be 4-4-4-4

Description

Cross-References

Synonyms (23)

Research Excerpts

Pharmacokinetics

Dosage Studied

Bioassays (3)

Research

Studies (18)

Market Indicators

Research Demand Index: 11.17

Study Types

be 4-4-4-4

Description

Cross-References

Synonyms (23)

Research Excerpts

Pharmacokinetics

Dosage Studied

Bioassays (3)

Research

Studies (18)

Market Indicators

Research Demand Index: 11.17

Study Types

Related Drugs (14)

Related Conditions (23)